DAVE vs. SRPT

Last updated Apr 2, 2026

Compare and contrast key facts about Dave Inc. (DAVE) and Sarepta Therapeutics, Inc. (SRPT).

Performance

DAVE vs. SRPT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Dave Inc. (DAVE) and Sarepta Therapeutics, Inc. (SRPT). The values are adjusted to include any dividend payments, if applicable.

DAVE vs. SRPT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
DAVE Dave Inc.	-21.66%	154.73%	936.61%	-9.64%	-97.17%	4.59%
SRPT Sarepta Therapeutics, Inc.	2.83%	-82.30%	26.09%	-25.58%	43.90%	22.85%

Fundamentals

Market Cap DAVE : $2.51B SRPT : $2.32B
EPS DAVE : $13.51 SRPT : -$8.11
PS Ratio DAVE : 4.92 SRPT : 1.05
PB Ratio DAVE : 7.10 SRPT : 2.03
Total Revenue (TTM) DAVE : $511.91M SRPT : $2.20B
Gross Profit (TTM) DAVE : $408.56M SRPT : -$1.05B
EBITDA (TTM) DAVE : $143.27M SRPT : -$778.95M

Returns By Period

In the year-to-date period, DAVE achieves a -21.66% return, which is significantly lower than SRPT's 2.83% return.

DAVE

• 1D: -0.37%
• 1M: -12.84%
• YTD: -21.66%
• 6M: -12.11%
• 1Y: 105.19%
• 3Y*: 205.89%
• 5Y*: —
• 10Y*: —

SRPT

• 1D: 1.70%
• 1M: 35.60%
• YTD: 2.83%
• 6M: 14.54%
• 1Y: -64.25%
• 3Y*: -45.65%
• 5Y*: -21.91%
• 10Y*: 1.03%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

DAVE vs. SRPT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DAVE

DAVE Risk / Return Rank: 78
DAVE Sharpe Ratio Rank: 79
DAVE Sortino Ratio Rank: 79
DAVE Omega Ratio Rank: 76
DAVE Calmar Ratio Rank: 81
DAVE Martin Ratio Rank: 74

SRPT

SRPT Risk / Return Rank: 18
SRPT Sharpe Ratio Rank: 15
SRPT Sortino Ratio Rank: 20
SRPT Omega Ratio Rank: 18
SRPT Calmar Ratio Rank: 12
SRPT Martin Ratio Rank: 23

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DAVE vs. SRPT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Dave Inc. (DAVE) and Sarepta Therapeutics, Inc. (SRPT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	DAVE	SRPT	Difference
Sharpe ratio Return per unit of total volatility	1.24	-0.59	+1.82
Sortino ratio Return per unit of downside risk	2.08	-0.42	+2.50
Omega ratio Gain probability vs. loss probability	1.26	0.93	+0.33
Calmar ratio Return relative to maximum drawdown	2.46	-0.80	+3.26
Martin ratio Return relative to average drawdown	4.60	-1.03	+5.63
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

DAVE vs. SRPT - Sharpe Ratio Comparison

The current DAVE Sharpe Ratio is 1.24, which is higher than the SRPT Sharpe Ratio of -0.59. The chart below compares the historical Sharpe Ratios of DAVE and SRPT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	DAVE	SRPT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.24	-0.59	+1.82
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.32	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.01	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.12	-0.02	-0.09

Correlation

The correlation between DAVE and SRPT is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

DAVE vs. SRPT - Dividend Comparison

Neither DAVE nor SRPT has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

DAVE vs. SRPT - Drawdown Comparison

The maximum DAVE drawdown since its inception was -99.01%, roughly equal to the maximum SRPT drawdown of -98.17%. Use the drawdown chart below to compare losses from any high point for DAVE and SRPT.

Drawdown Indicators

	DAVE	SRPT	Difference
Max Drawdown Largest peak-to-trough decline	-99.01%	-98.17%	-0.84%
Max Drawdown (1Y) Largest decline over 1 year	-44.67%	-81.26%	+36.59%
Max Drawdown (5Y) Largest decline over 5 years	—	-92.72%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-93.33%	—
Current Drawdown Current decline from peak	-62.10%	-87.62%	+25.52%
Average Drawdown Average peak-to-trough decline	-69.90%	-68.02%	-1.88%
Ulcer Index Depth and duration of drawdowns from previous peaks	23.86%	63.52%	-39.66%

Volatility

DAVE vs. SRPT - Volatility Comparison

The current volatility for Dave Inc. (DAVE) is 16.48%, while Sarepta Therapeutics, Inc. (SRPT) has a volatility of 34.93%. This indicates that DAVE experiences smaller price fluctuations and is considered to be less risky than SRPT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DAVE	SRPT	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.48%	34.93%	-18.45%
Volatility (6M) Calculated over the trailing 6-month period	49.33%	70.71%	-21.38%
Volatility (1Y) Calculated over the trailing 1-year period	85.56%	109.93%	-24.37%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	98.18%	69.76%	+28.42%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	98.18%	75.46%	+22.72%

Financials